CRS was associated with peak IL-6 levels throughout the treatment period; however, no statistically significant difference was noted in IL-6 peak levels between patients with and without ICANS, patients with CRS concomitant ICANS, and others. The gene discussed is IL6; the disease is congenital rubella syndrome.